All In MedTech

Device Trial Radar · NCT04471909

NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

A Multi-arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch

Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Oct 20, 2020

Primary completion

Oct 2025

Study completion Oct 2029

Sponsor

Lead sponsor
Endospan Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jul 15, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.

Conditions

  • Aortic Dissection
  • Aortic Aneurysm
  • Intramural Hematoma
  • Penetrating Aortic Ulcer

Interventions

  • NEXUS Aortic Stent Graft SystemDevice

    Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta. Ascending Stent Graft intended to be deployed in the Ascending Aorta. OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device Technical FailureTime frame: 30 Days
  2. Clinical FailureTime frame: 30 Days

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama · Recruiting

  • University of California San Diego Medical Center

    La Jolla, California · Recruiting

  • UC Davis Health

    Sacramento, California · Completed

29 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.